Addvise logo
sv_SE
sv_SE
search

ADDvise Group explores the conditions for carrying out a directed new share issue of B shares of approximately SEK 100 million

By

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. … Read more

Year-end report 2023, January 1-December 31

By

ADDvise delivers its strongest quarter to date and surpasses financial targets for 2023. Net sales increased by 24% and EBITDA amounted to a record SEK 126 million, corresponding to an EBITDA margin of 32%. October-December 2023 Net revenue for the period was SEK 397.0 million (320.3), an increase of 24.0%. On an organic basis, net … Read more

ADDvise receives order worth EUR 2.1 million

By

ADDvise Group’s subsidiary Labplan has received an order from the pharmaceutical company Eli Lilly. The order is worth approximately EUR 2.1 million and involves advanced laboratory instruments for quality control purposes. The instruments will be used in a new manufacturing facility for biologic pharmaceuticals in Limerick, Ireland. Delivery of the order is scheduled to the … Read more

ADDvise receives order worth USD 2.5 million

By

ADDvise Group’s subsidiary MRC Systems has received an order from SaudiVax. The company is a biotechnology company specialized in the development and production of vaccines and biopharmaceuticals. The order is worth approximately USD 2.5 million and involves design, installation, and commissioning of a cleanroom and associated accessories. The facility is located in the Kingdom of … Read more

ADDvise receives order worth USD 3 million

By

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Leader Life Sciences, part of Dubai-based Leader Healthcare Group. Leader Life Sciences is a specialist company aiming to introduce ground-breaking scientific technologies and solutions in the fields of biomedical sciences, biotechnology, drug discovery, environmental sciences, and precision medicine. The order is worth approximately … Read more

ADDvise acquires Labplan Ltd.

By

ADDvise Group has entered into a share purchase agreement with the owners of Labplan Ltd. (“Labplan”) regarding the acquisition of all shares of Labplan. Closing takes place today. Labplan, based in Kildare, Ireland, is a distributor of specialized advanced instruments, consumables and service to the life science and biopharmaceutical industry. The company serves large multi-national … Read more

ADDvise decides not to complete the acquisition of Innovative Endoscopy Components, LLC.

By

Innovative Endoscopy Components, LLC. which ADDvise signed a letter of intent to acquire on June 15, 2023, has during the subsequent due diligence not performed in line with initial expectations as regards profitability. ADDvise and the sellers have therefore agreed to terminate discussions. For further information, please contact: Rikard Akhtarzand, CEO +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se … Read more

ADDvise acquires Axelerist, Inc.

By

ADDvise Group has entered into a share purchase agreement with the owner of Axelerist, Inc. (“Axelerist”) regarding the acquisition of all shares of Axelerist. Closing of the acquisition takes place today. Axelerist, based in Yorktown Heights, New York, is a leading provider of tailored rental and purchase solutions of MedTech- and laboratory equipment for clinical … Read more

Interim report 2023, January 1-September 30

By

July-September 2023 Net revenue for the period was SEK 321.1 million (237.0), an increase of 35.5%. Organic growth was 18.0%. Orders received for the period was SEK 360.0 million (268.4), an increase of 34.1%. Organic growth was 30.1%. EBITDA for the period was SEK 93.6 million (39.2) Profit/loss for the period was SEK 34.8 million … Read more